175 related articles for article (PubMed ID: 29342450)
1. Occupational allergic respiratory disease (rinoconjunctivitis and asthma) in a cheese factory worker.
Gómez Torrijos E; García Rodriguez C; Veleiro Pérez B; Bartolomé B; Prado Barragan M; Garcia Rodriguez R
J Allergy Clin Immunol Pract; 2018; 6(4):1416-1417. PubMed ID: 29342450
[No Abstract] [Full Text] [Related]
2. Anti-IgE treatment: an update.
Babu KS; Arshad SH; Holgate ST
Allergy; 2001 Dec; 56(12):1121-8. PubMed ID: 11736740
[No Abstract] [Full Text] [Related]
3. Aspirin tolerance in patients with nonsteroidal anti-inflammatory drug-exacerbated respiratory disease following treatment with omalizumab.
Phillips-Angles E; Barranco P; Lluch-Bernal M; Dominguez-Ortega J; López-Carrasco V; Quirce S
J Allergy Clin Immunol Pract; 2017; 5(3):842-845. PubMed ID: 28117272
[No Abstract] [Full Text] [Related]
4. The use of anti-IgE therapy beyond allergic asthma.
Stokes JR; Casale TB
J Allergy Clin Immunol Pract; 2015; 3(2):162-6. PubMed ID: 25609342
[TBL] [Abstract][Full Text] [Related]
5. Anti-IgE monoclonal antibody (omalizumab) in the treatment of atopic asthma and allergic respiratory diseases.
D'Amato G; Liccardi G; Noschese P; Salzillo A; D'Amato M; Cazzola M
Curr Drug Targets Inflamm Allergy; 2004 Sep; 3(3):227-9. PubMed ID: 15379589
[TBL] [Abstract][Full Text] [Related]
6. [Respiratory allergies in the child and the adult].
Magnan A
Rev Prat; 2004 Jan; 54(2):189-98. PubMed ID: 15086062
[No Abstract] [Full Text] [Related]
7. Anaphylaxis due to progesterone hypersensitivity successfully treated with omalizumab.
Heffler E; Fichera S; Nicolosi G; Crimi N
J Allergy Clin Immunol Pract; 2017; 5(3):852-854. PubMed ID: 28258855
[No Abstract] [Full Text] [Related]
8. Use of omalizumab in uncontrolled chronic spontaneous urticaria also improved latex-induced contact urticaria.
Di Leo E; Calogiuri G; Macchia L; Nettis E
J Allergy Clin Immunol Pract; 2019 Jan; 7(1):300-302. PubMed ID: 29802908
[No Abstract] [Full Text] [Related]
9. Fatal asthma after omalizumab and controller therapy discontinuation.
Lombardi C; Cottini M; Passalacqua G
Eur Ann Allergy Clin Immunol; 2018 Jul; 50(5):235-236. PubMed ID: 30039694
[No Abstract] [Full Text] [Related]
10. Omalizumab in idiopathic anaphylaxis.
Warrier P; Casale TB
Ann Allergy Asthma Immunol; 2009 Mar; 102(3):257-8. PubMed ID: 19354075
[No Abstract] [Full Text] [Related]
11. The anti-inflammatory effects of omalizumab confirm the central role of IgE in allergic inflammation.
Holgate S; Casale T; Wenzel S; Bousquet J; Deniz Y; Reisner C
J Allergy Clin Immunol; 2005 Mar; 115(3):459-65. PubMed ID: 15753888
[TBL] [Abstract][Full Text] [Related]
12. IgE-Related Chronic Diseases and Anti-IgE-Based Treatments.
Navinés-Ferrer A; Serrano-Candelas E; Molina-Molina GJ; Martín M
J Immunol Res; 2016; 2016():8163803. PubMed ID: 28097159
[TBL] [Abstract][Full Text] [Related]
13. Occupational rhinitis caused by rice flour in a pizzeria worker.
Antolin-Amerigo D; Rodríguez-Rodríguez M; Barbarroja Escudero J; Pérez Bustamante MS; Jimeno Nogales L; Guerrero Ríos JA; Mohedano-Vicente E; Alvarez-Mon M
Allergol Immunopathol (Madr); 2013; 41(2):130-3. PubMed ID: 22503558
[No Abstract] [Full Text] [Related]
14. Omalizumab: an effective anti-IgE treatment for allergic asthma and rhinitis.
Casale TB;
Drugs Today (Barc); 2004 Apr; 40(4):367-76. PubMed ID: 15190389
[TBL] [Abstract][Full Text] [Related]
15. [Omalizumab, recombinant humanized monoclonal antibody anti-IgE -- new fields of studies on the therapeutic indications].
Kupryś-Lipińska I; Kuna P
Pneumonol Alergol Pol; 2009; 77(1):43-51. PubMed ID: 19308909
[TBL] [Abstract][Full Text] [Related]
16. Treatment of moderate to severe pediatric asthma: Omalizumab and potential future use of monoclonal antibodies.
Wright LS; Phipatanakul W
Ann Allergy Asthma Immunol; 2016 Jul; 117(1):17-20. PubMed ID: 27371967
[No Abstract] [Full Text] [Related]
17. Efficacy and tolerability of anti-immunoglobulin E therapy with omalizumab in patients with concomitant allergic asthma and persistent allergic rhinitis: SOLAR.
Vignola AM; Humbert M; Bousquet J; Boulet LP; Hedgecock S; Blogg M; Fox H; Surrey K
Allergy; 2004 Jul; 59(7):709-17. PubMed ID: 15180757
[TBL] [Abstract][Full Text] [Related]
18. Successful treatment with omalizumab in challenge confirmed exercise-induced anaphylaxis.
Christensen MJ; Bindslev-Jensen C
J Allergy Clin Immunol Pract; 2017; 5(1):204-206. PubMed ID: 27839749
[No Abstract] [Full Text] [Related]
19. Omalizumab in children with severe allergic disease: a case series.
Crisafulli G; Caminiti L; Chiera F; Arasi S; Salzano G; Panasiti I; Barbalace A; Pajno GB
Ital J Pediatr; 2019 Jan; 45(1):13. PubMed ID: 30642367
[TBL] [Abstract][Full Text] [Related]
20. The relationship between allergen immunotherapy and omalizumab for treating asthma.
Braido F; Corsico A; Rogkakou A; Ronzoni V; Baiardini I; Canonica GW
Expert Rev Respir Med; 2015 Apr; 9(2):129-34. PubMed ID: 25578528
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
